Lonza Launches New Cell Line for Higher Potency Antibody Development

Published on: 
BP Elements, BioPharm International's BP Elements, December 2023, Volume 2, Issue 12

Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.

On Nov. 14, 2023, Lonza announced the launch of its new cell line, GS Effex, which is intended for the development of therapeutic antibodies with enhanced potency. Derived from the company’s GS Xceed cell line, GS Effex was developed to meet the development needs for more sophisticated therapeutic antibodies. The new cell line combines the characteristics of good cell growth with the ability to produce therapeutic antibodies with increased potency.

GS Effex is a stable, scalable, and productive cell line that produces Fc domains free of fucose, which, according to Lonza, increases the antibody-dependent cellular cytotoxicity (ADCC) function and therapeutic potency of the final antibody. GS Effex is available under license or as a complete service offering.

"Lonza is committed to providing our customers with the right tools to develop their novel therapies. Leveraging more than 35 years of protein expression expertise, more than 75 molecules have been manufactured and brought to the clinic using our expression platforms,” said Ulrich Osswald, vice-president, Licensing, Lonza, in a company press release. “The new GS Effex cell line represents an enhanced solution especially relevant for the oncology field since improved ADCC represents a vital enhancement of the therapeutic success of an antibody product."


“At Lonza, we develop and invest in novel, disruptive technologies with potential to transform the development, analytics, and manufacturing of established and novel biotherapeutics,” said Atul Mohindra, head of Biologics R&D, Lonza, in the press release. “The GS Effex cell line provides a reliable protein expression platform with the needs of our customers in mind. This cell line enables the efficient production of monoclonal antibodies with increased ADCC, while also delivering the required product quality and efficacy profile.”

Source: Lonza